

HEB



JOHP

## Journal of Hospital Pharmacy

An Official Publication of Bureau for Health & Education Status Upliftment

(Constitutionally Entitled As Health-Education, Bureau)

### A detailed review of drug *Tafamidis Meglumine*

Supriya Khanra<sup>1\*</sup>, Ankit Sharma<sup>1</sup>, Sudipta Nayak<sup>2</sup>, Nidhi Gairola<sup>1</sup>, Tarun Parashar<sup>1</sup>, Jaswant Singh<sup>1</sup>

1. Uttaranchal University, Uttaranchal Institute of Pharmaceutical Sciences(UIPS), Deheradun 248007, India
2. College of Pharmaceutical Sciences(CPS), Odisha 752002, India

Email: [serviceheb@gmail.com](mailto:serviceheb@gmail.com)

#### ABSTRACT:

Vyndaquel (Tefamidis Meglumine) is transthyretin (TTR) class of drug which is basically used for treatment of cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. It is soft gelatine capsules which standard dose 20 mg Vyndaquel the drug which route of administration is Oral. Molecular formula of Vyndaquel is [C21H24Cl2N2O8](#), which chemical name is d-glucitol, 1-deoxy-1-(methyl amino)-, 2-(3, 5-dichlorophenyl)-6benzoxazolecarboxylate. Molecular weight of this drug is 503.3 g/mol. Maximum daily dosage of this drug is 80 mg/day.

**Keywords:** ATTR-CM, Soft gelatine capsules, TTR, Vyndaquel.

#### Access this Article Online

Website: <http://www.journalofhospitalpharmacy.in>

Received on 01/07/2021

Accepted on 14/07/2021 © HEB All rights reserved

Quick Response Code:

